An interventional study of NKG2D CAR-NK in Ovarian Cancer, sponsored by Hangzhou Cheetah Cell Therapeutics Co., Ltd. Status unknown at 1 site in China. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-03-28.
Sponsored by Hangzhou Cheetah Cell Therapeutics Co., Ltd · Not applicable, Interventional, and Treatment
This trial will explore the maximum tolerated dose (MTD)of NKG2D CAR-NK cells in the treatment of platinum-resistant, relapsed epithelial ovarian cancer in a dose-escalation manner, and observe the clinical safety and efficacy.
2,695 studies on the registry are indexed under Ovarian Neoplasms; 727 are open to participants now.
This study's planned enrollment of 18 is below the median of 60 across 2,030 interventional studies indexed under Ovarian Neoplasms.
Browse Ovarian Neoplasms studies →Hangzhou Cheetah Cell Therapeutics Co., Ltd is the lead sponsor of 2 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Biological: NKG2D CAR-NK
Lymphodepleting chemotherapy followed by NKG2D CAR-NK infusion
DLT
Dose-Limiting Toxicity
Time frame: 28 days
MTD
Maximal Tolerable Dose
Time frame: 28 days
Plan to share: No
No publications or documents are linked to this record.
This study is status unknown, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hangzhou Cheetah Cell Therapeutics Co., Ltd